NuVasive Announces Conference Call and Webcast of Second Quarter 2021 Results
NuVasive (NASDAQ: NUVA) announced it will release its second quarter 2021 earnings results on July 28, 2021, after market close. A conference call will follow at 4:30 p.m. ET to discuss financial performance. The call can be accessed via dial-in or through a live webcast on the company's Investor Relations page. NuVasive, a leader in spine technology, focuses on minimally disruptive surgical solutions and has over $1 billion in net sales and approximately 2,700 employees globally.
- Strong market presence with over $1 billion in net sales.
- Leader in spine technology innovation, focused on minimally invasive surgical solutions.
- None.
SAN DIEGO, July 14, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the Company will release its second quarter 2021 earnings results on Wednesday, July 28, 2021, after the close of the market.
NuVasive will hold a conference call on Wednesday, July 28, 2021, at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results of its financial performance for the second quarter 2021. The dial-in numbers are 1-877-407-9039 for domestic callers and 1-201-689-8470 for international callers. A live webcast of the conference call will be available online from the Investor Relations page of the Company's website at www.nuvasive.com.
After the live event, the webcast will remain available on NuVasive's website for 30 days. In addition, an audio replay of the call will be available until August 4, 2021. The replay dial-in numbers are 1-844-512-2921 for domestic callers and 1-412-317-6671 for international callers. Please use pin number: 13720558.
About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, with a mission to transform surgery, advance care, and change lives. The Company's less-invasive, procedurally integrated surgical solutions are designed to deliver reproducible and clinically proven outcomes. The Company's comprehensive procedural portfolio includes surgical access instruments, spinal implants, fixation systems, biologics, software for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative neuromonitoring technology and service offerings. With more than
Forward-Looking Statements
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, but are not limited to, the risk that NuVasive's net sales or earnings projections may turn out to be inaccurate because of the preliminary nature of the forecasts; the risk of further adjustment to financial results or future financial expectations; unanticipated difficulty in selling products, generating net sales or producing expected profitability; and those other risks and uncertainties more fully described in NuVasive's news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvasive-announces-conference-call-and-webcast-of-second-quarter-2021-results-301333962.html
SOURCE NuVasive, Inc.
FAQ
When will NuVasive release its Q2 2021 earnings results?
How can I listen to NuVasive's Q2 2021 earnings call?
What is NuVasive's stock symbol?
What is NuVasive's primary focus?
